Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 (the “Agreement”), to further improve the terms of its OCABSA financing program in the context of the closing of the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell, have now been completed as planned (see TxCell’s press release dated July 23, 2018). The OCABSA financing program is therefore terminated.
Immunicum AB today announced that Nasdaq Stockholm decided to halt trading in the Company’s share as a result of share price movements.
Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK.
Facility is acquired from Porton Pharma Solutions Ltd., and operated with GMP compliance.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.
Akari Therapeutics, Plc today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $20 million with Aspire Capital Fund, LLC
LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of Berry and Associates, premier supplier of specialty oligo reagents.
Clinigen Group plc has agreed to acquire iQone Healthcare Holding, a privately owned Swiss based speciality pharmaceutical business for an initial consideration of €7.5 million (£6.7 million) on a cash free, debt free basis.